Last reviewed · How we verify

Experimental: Primary Cohort

University of Chicago · FDA-approved active Small molecule Quality 5/100

Experimental: Primary Cohort is a Small molecule drug developed by University of Chicago. It is currently FDA-approved. Also known as: azelastine.

At a glance

Generic nameExperimental: Primary Cohort
Also known asazelastine
SponsorUniversity of Chicago
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Experimental: Primary Cohort

What is Experimental: Primary Cohort?

Experimental: Primary Cohort is a Small molecule drug developed by University of Chicago.

Who makes Experimental: Primary Cohort?

Experimental: Primary Cohort is developed and marketed by University of Chicago (see full University of Chicago pipeline at /company/university-of-chicago).

Is Experimental: Primary Cohort also known as anything else?

Experimental: Primary Cohort is also known as azelastine.

What development phase is Experimental: Primary Cohort in?

Experimental: Primary Cohort is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing